本帖最后由 老马 于 2013-3-13 13:43 编辑
' q3 u7 I% X7 N- U$ R8 m. Z4 x& o& D0 }
健择（吉西他滨）+顺铂+阿瓦斯汀! G9 g, u+ t+ I
Gemzar +Cisplatin + Avastin
, `: v; V# C" W) j; k& Qhttp://annonc.oxfordjournals.org/content/21/9/1804.full' i9 g& E7 x6 L4 y3 ^2 b
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ) C) F* m& Y7 ?% Y9 ]. m2 d
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 4 ~7 E% y; @9 z" M& s/ f
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ f( U+ Y. b( P( ^
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1035)
1 E. H6 d- d. `, V
华为网盘附件：, M5 d- R; r' v7 E7 \0 d
【华为网盘】ava.JPG& m; B) }% H) j: p! A8 ~, o
|
显身卡
